News | May 18, 2026
Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The target reach is of more than 30 million young people and caregivers across 21 countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
